To verify the hypothesis, we retrospectively collected a cohort of 261 CRC samples harboring BRAF mutation and divided them into two groups: 174 patients in the RNF43 wild-type group and 87 patients in the RNF43 mutant group (Supplementary Table 1). This evidence concerns the gene BRAF and colorectal carcinoma.